Investornewsbreaks Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In Networknewsaudio Release On Innovative Therapeutics Pipeline

(MENAFN- Investor Brand Network) Oncotelic Therapeutics (OTCQB: OTLC) is featured in a new NetworkNewsAudio Audio Press Release (APR) titled“Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth.” The release highlights the leadership of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy and nanomedicine. Dr. Trieu previously developed Abraxane(R), a nanotechnology-based formulation that transformed treatment for breast, lung and pancreatic cancers, and advanced Cynviloq(TM), a novel micellar paclitaxel therapy. The feature underscores how his track record and expertise position Oncotelic to advance pioneering therapies with strong market potential.

To view the full press release, visit

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company's mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu's leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic's strategic position in oncology and rare disease therapeutics.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company's newsroom at OTLC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: /Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

MENAFN19092025000224011066ID1110085601